John Rogers’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-11,198
Closed -$1.52M 115
2022
Q4
$1.52M Buy
11,198
+174
+2% +$21.8K 0.02% 106
2022
Q3
$1.21M Sell
11,024
-318
-3% -$40.3K 0.01% 104
2022
Q2
$1.5M Sell
11,342
-630
-5% -$82.7K 0.02% 100
2022
Q1
$1.59M Sell
11,972
-398
-3% -$47.7K 0.01% 101
2021
Q4
$1.44M Sell
12,370
-804
-6% -$94.6K 0.01% 101
2021
Q3
$1.58M Sell
13,174
-37
-0.3% -$4.31K 0.01% 104
2021
Q2
$1.58M Sell
13,211
-184
-1% -$20.2K 0.01% 102
2021
Q1
$1.33M Buy
13,395
+192
+1% +$19.3K 0.01% 110
2020
Q4
$1.32M Buy
+13,203
New +$1.4M 0.01% 125

Other funds holding AZN

John Rogers's AZN Position: Q1 2023 in Review

John Rogers sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 11,198 shares — an estimated $1.52M sold.

John Rogers first reported a position in AZN in Q4 2020 and held it in 9 quarters. The position peaked at $1.59M in Q1 2022. 1,056 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

  • John Rogers reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
  • John Rogers sold 11,198 AstraZeneca shares in Q1 2023, an estimated $1.52M.
  • John Rogers first reported a position in AstraZeneca in Q4 2020 and held it in 9 quarters.
  • John Rogers's AstraZeneca position peaked at $1.59M in Q1 2022.
  • 1,056 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Ariel Investments's 13F filing for Q1 2023, filed 12 May 2023.